SOUTH SAN FRANCISCO, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today reported full-year 2016 financial results. 

As of December 31, 2016, CytomX had cash and cash equivalents and short-term investments of $181.9 million. Based upon its current operating plan, the Company expects its existing capital resources will be sufficient to fund operations into 2019.

“Over the past year, CytomX has transformed from a research organization to a clinical-stage company, bringing us one step closer to realizing our vision of transforming lives with safer and more effective therapies,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics. “With our lead program, CX-072, in the clinic and CX-2009 closely behind, together with our world-class pharmaceutical partnerships, we are advancing a broad and deep pipeline of differentiated Probody therapeutics that are focused on some of the most compelling targets for the treatment of cancer.”

2016 Business Highlights and Recent Developments

PROCLAIM-CX-072 (PD-L1 Probody) Program

  • Enrollment is underway in the PROCLAIM clinical study of CX-072, a PD-L1-targeting Probody therapeutic for the treatment of cancer patients. 
  • Clinical data is expected to begin to emerge in late 2017, and throughout 2018.

CX-2009 (CD166 Probody Drug Conjugate) Program

  • Following completion of GMP manufacturing and GLP toxicity studies in 2016, the IND filing for CX-2009 remains on track for the first half of 2017.
  • CX-2009 is a first-in-class Probody drug conjugate targeting the highly expressed tumor antigen, CD166.
  • Clinical data is expected to begin to emerge in late 2017, and throughout 2018.


  • CytomX continues to forge biopharmaceutical partnerships that retain meaningful downstream rights to extend the reach of our technology and in order to fund its wholly-owned programs.
  • As part of our ongoing collaboration, Bristol-Myers Squibb selected the third and fourth targets and selected a CTLA-4 clinical candidate for a total of $25 million in payments to CytomX in 2016.
  • In April 2016, CytomX entered into a collaboration with AbbVie to co-develop and co-commercialize Probody Drug Conjugates against CD71 and up to two additional targets to be selected by AbbVie. CytomX received an upfront payment of $30 million.

Full-Year Financial Results
Cash, cash equivalents and investments totaled $181.9 million as of December 31, 2016, compared to $186.7 million as of December 31, 2015. The decrease reflects cash used in operations, partially offset by a $30 million upfront payment received from AbbVie in connection with the development and collaboration agreements entered into in April 2016, and $25 million in milestone payments received from Bristol-Myers Squibb in connection with its third target selection in January 2016, and fourth target selection in December 2016.

Research and development expenses were $54.8 million for the year ended December 31, 2016, compared to $28.4 million for the year ended December 31, 2015. The increase was primarily attributable to $9.6 million in manufacturing costs for the Company’s CX-072, CX-2009 and CX-2029 programs, $4.5 million in laboratory and professional services and supplies, $3.1 million in personnel-related expenses due to an increase in headcount, $3.1 million in non-cash stock-based compensation due to higher stock valuation, $2.4 million to advance CX-072 into Phase 1/2 clinical development, $1.7 million in royalty payments triggered by the payments from Bristol-Myers Squibb’s third and fourth target selections, clinical candidate selection, as well as upfront payments from AbbVie, and $1.6 million in facilities-related expenses due to a move to a larger facility in October 2016.

General and administrative expenses were $19.9 million for the year ended December 31, 2016, compared to $12.6 million for the year ended December 31, 2015. The increase was predominantly due to $3.2 million in non-cash stock based compensation due to higher stock valuation, $2 million in professional service and outside service expenses, $1.8 million in personnel-related expenses due to an increase in headcount and $0.4 million in facilities-related expense due to a move to a larger facility in October 2016.

About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The Company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and develop first-in-class cancer therapeutics against difficult-to-drug targets, such as CD166. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.  The Company’s lead program, CX-072, a wholly-owned PD-L1-targeting Probody therapeutic, is being evaluated in a Phase 1/2 study. The Investigational New Drug filing for CX-2009 is slated for the first half of 2017.  CX-2009 is a first-in-class Probody drug conjugate targeting the highly expressed tumor antigen, CD166.  Both clinical trials are modules within PROCLAIM (Probody Clinical Assessment In Man), an international umbrella clinical trial program that provides clinical trial sites with access to the company’s novel therapies under one central protocol. In addition to its proprietary programs, CytomX is collaborating with strategic partners including AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit

CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential efficacy of CytomX’s product candidates, the Company’s ability to develop and advance product candidates into and successfully complete clinical trials, including the Company’s Phase 1/2 clinical trial of CX-072 and the timing of any future clinical trials. One of our product candidates under our Probody platform is in the initial stages of clinical development and our other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties. Projected net cash utilization and capital resources are subject to substantial risk of variance based on a wide variety of factors that can be difficult to predict.  Applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in the Company’s Annual Report on Form 10-K filed with the SEC on March 2, 2017. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

(in thousands, except share and per share data)
  Year Ended December 31, 
  2016    2015    2014 
Revenues $12,845  $5,941  $2,751 
Revenues from related parties  2,198   1,771   2,326 
Total revenues  15,043   7,712   5,077 
Operating expenses:            
Research and development  54,755   28,357   28,302 
General and administrative  19,874   12,558   6,540 
Total operating expenses  74,629   40,915   34,842 
Loss from operations  (59,586)  (33,203)  (29,765)
Interest income  2,425   1,315   7 
Interest expense  (1,689)  (1,732)  (487)
Other income (expense), net  (69)  (1,744)  (55)
Loss before provision for (benefit from) income taxes  (58,919)  (35,364)  (30,300)
Provision for (benefit from) income taxes  (19)  10   10 
Net loss  (58,900)  (35,374)  (30,310)
Accretion to redemption value and cumulative dividends on preferred stock     (6,705)  (4,566)
Net loss attributable to common stockholders $(58,900) $(42,079) $(34,876)
Net loss per share attributable to common stockholders, basic and diluted $(1.63) $(4.90) $(35.25)
Shares used to compute net loss per share attributable to common stockholders, basic and diluted        36,234,732   8,595,247   989,453 

(in thousands, except share and per share data)
 December 31,   December 31, 
 2016  2015 
Current assets:       
Cash and cash equivalents$104,645  $59,822 
Short-term investments 77,293   126,889 
Accounts receivable 2,159   372 
Related party accounts receivable 154   372 
Prepaid expenses and other current assets 3,896   2,299 
Total current assets 188,147   189,754 
Property and equipment, net 4,392   3,481 
Intangible assets 1,750   1,750 
Goodwill 949   949 
Restricted cash 917   917 
Other assets 2,973   364 
Total assets$199,128  $197,215 
Liabilities, Convertible Preferred Stock and Stockholders' Equity       
Current liabilities:       
Accounts payable$6,596  $4,697 
Accrued liabilities 8,824   4,912 
Deferred revenues, current portion 20,347   6,130 
Total current liabilities 35,767   15,739 
Deferred revenue, net of current portion 83,803   54,703 
Deferred tax liability 513   507 
Other long-term liabilities 566   198 
Total liabilities 120,649   71,147 
Stockholders' equity       
Convertible preferred stock, $0.00001 par value; 10,000,000 shares  authorized at December 31, 2016 and 2015; no shares issued and outstanding at December 31, 2016 and 2015, respectively     
Common stock, $0.00001 par value; 75,000,000 shares authorized at December 31, 2016 and 2015; 36,490,169 and 36,033,209 shares issued and outstanding at December 31, 2016 and 2015, respectively 1   1 
Stockholders notes receivable    (78)
Additional paid-in capital 254,871   243,687 
Accumulated other comprehensive loss (27)  (76)
Accumulated deficit (176,366)  (117,466)
Total stockholders' equity 78,479   126,068 
Total liabilities, convertible preferred stock and stockholders' equity$199,128  $197,215 


Corporate Communications Contact: 
Canale Communications
Ian Stone

Investor Contact:
Trout Group
Pete Rahmer